Bio Essence (BIOE) Asset Writedowns and Impairment (2021)

Bio Essence (BIOE) recorded quarterly Asset Writedowns and Impairment of $8235.0 in Q4 2021, up 2067.11% quarter-over-quarter from $380.0 in Q1 2021.

Bio Essence (BIOE) Asset Writedowns and Impairment (2021) Analysis & Trends

Bio Essence's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $8235.0 for Q4 2021.

In Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $8235.0; the TTM figure through Dec 2024 stood at $8235.0 (changed N/A YoY), while the FY2024 annual figure was $1.1 million, changed N/A from the prior year.
Asset Writedowns and Impairment was $8235.0 for Q4 2021 at Bio Essence, up from $380.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $8235.0 in Q4 2021 to a low of $380.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Bio Essence	-	-	319,353.00

Download Data